HER2-Positive Breast Cancer Medical Services in China

HER2-positive breast cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein, detected via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Accounting for approximately 15–20% of invasive breast cancers, it exhibits rapid proliferation, higher recurrence risk, and poorer prognosis without targeted intervention. However, the advent of HER2-directed therapies—including monoclonal antibodies (tr pertuzumab), antibody-drug conjugates (fam-trastuzumab deruxtecan-nxki), and tyrosine kinase inhibitors (lapatinib, tucatinib)—has transformed outcomes, significantly improving progression-free and overall survival, especially when integrated into neoadjuvant, adjuvant, or metastatic treatment regimens.

China offers compelling advantages for international patients seeking HER2-positive breast cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—host nationally certified HER2 testing laboratories and multidisciplinary tumor boards with extensive experience in complex cases. Advanced imaging (3.0T MRI, digital PET-CT), robotic-assisted surgery, and early access to globally approved biologics—including biosimilar trastuzumab with equivalent efficacy and safety profiles—enhance therapeutic precision. Clinical outcomes align with international benchmarks: five-year disease-free survival exceeds 85% in early-stage patients receiving guideline-concordant dual HER2 blockade. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality—drugs, diagnostics, and hospital stays remain rigorously regulated by China’s National Medical Products Administration (NMPA).

As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital accreditation, coordinating appointments with certified oncologists, providing itemized, transparent pricing in advance, arranging visa support, interpreters, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

Treatment Options & Itemized Cost Breakdown: HER2-Positive Breast Cancer

Non-Surgical/Medical Therapies

*Eligibility*: Confirmed HER2-positive status (IHC 3+ or FISH-amplified), no contraindications to targeted therapy.

• •Neoadjuvant/Adjuvant Dual HER2 Blockade (Trastuzumab + Pertuzumab)

- Trastuzumab (440 mg IV): $580–$620 - Pertuzumab (420 mg IV): $1,150–$1,280 - *Supportive care & monitoring*: - Cardiac echo (baseline + q3mo): $45–$65 - LVEF monitoring (BNP + ECG): $25–$35 - Monthly CBC/LFTs: $18–$22

• •Adjuvant Trastuzumab Monotherapy (1 year)

- *Infusion & nursing fees (per cycle)*: $110–$140

• •T-DM1 (Ado-trastuzumab emtansine) for residual disease post-neoadjuvant

- *Pre-infusion labs (CBC, LFTs, bilirubin)*: $32–$40

Surgical/Procedural Interventions

*Eligibility*: Clinically resectable tumor (cT1–4, N0–2, M0); adequate cardiac/respiratory reserve.

• •Lumpectomy + Sentinel Lymph Node Biopsy (SLNB)

- *Pre-op workup (mammogram + ultrasound + core biopsy)*: $380–$460 - *Pathology (HER2/FISH retesting, SLN analysis)*: $290–$340

• •Mastectomy ± Immediate Implant Reconstruction

- *Implant reconstruction (silicone)*: $5,200–$6,300 - *Pre-op MRI (if indicated for multifocality)*: $420–$490

• •Axillary Lymph Node Dissection (ALND)

Special/Complex Scenarios

• •Metastatic Disease (CNS involvement):

- *Brain MRI (with contrast)*: $310–$370

• •Cardiac toxicity requiring LVEF recovery:

Quick Selection Guide

• •Early-stage, <65 y, no comorbidities: Lumpectomy + dual HER2 blockade — optimal balance of efficacy, organ preservation, and cost (~$14,200–$16,800 total)
• •Locally advanced, budget-constrained: Mastectomy + trastuzumab monotherapy — avoids high-cost pertuzumab/T-DM1 (~$13,500–$15,100)
• •Elderly (>75 y) or severe cardiac disease: Trastuzumab monotherapy + radiotherapy (if lumpectomy deferred) — minimizes procedural risk (~$10,200–$11,800)
• •Residual disease post-neoadjuvant: T-DM1 — standard-of-care despite higher upfront cost (~$34,000–$37,500)
• •Metastatic with brain mets: Tucatinib-based regimen — only FDA/NMPA-approved CNS-penetrant option (~$20,000–$22,500 initial phase)